S&P 500 7,691.39 0.42% Nasdaq 26,430.89 1.11% Dow Jones 51,966.03 0.07% Russell 2000 2,728.30 0.25% Gold 4,157.50 0.56% Bitcoin-USD 81,894.64 0.14% AAPL 342.94 0.15% MSFT 533.52 0.84% GOOGL 344.18 1.05% AMZN 262.45 4.98% NVDA 217.09 1.38% META 705.44 0.55% TSLA 368.06 3.76%

NASDAQ : ACAD

ACAD logoAcadia Pharmaceuticals Inc. (ACAD)Healthcare : Biotechnology
You need sign in

$19,80

+0.68 (+3.56%) today

After-hours $19,80 +0.68 (+3.56%)
Overview News Earnings Leadership

Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

CEO:
Catherine E. Owen Adams
Country:
US
Full-time employees:
797
Address:
12830 El Camino Real, San Diego, CA, 92130
IPO date:
May 27, 2004

Open

$19,33

High

$19,84

Low

$19,11

Mkt. cap

3.41B

Avg. vol.

1.83M

Volume

1.30M

52-wk high

$30,96

52-wk low

$18,39

Shares outstanding

172.31M